Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis - Full Text View

Purpose

The present study will aim to evaluate the efficacy of milnacipran in the treatment of pain due to osteoarthritis (OA), that is, to determine whether milnacipran provides superior efficacy to placebo in patients with OA. Milnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI) that is currently approved in the United States in the treatment of major depressive disorder and fibromyalgia. There is increased evidence to suggest that SNRIs may be effective in the treatment of chronic pain conditions, such as OA.

The hypothesis in this study is that the survival time (time from randomization to loss of efficacy) of milnacipran group is superior to that of placebo group.

Condition	Intervention	Phase
Osteoarthritis	Drug: Milnacipran Drug: Placebo	Phase 4


Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	A Double-Blind, Placebo-Controlled, Enriched Enrollment Randomized Withdrawal Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis

Resource links provided by NLM:

MedlinePlus related topics: Osteoarthritis

Drug Information available for: Milnacipran Levomilnacipran Milnacipran hydrochloride

U.S. FDA Resources

Further study details as provided by Analgesic Solutions:

Primary Outcome Measures:

Time to loss of efficacy in the Double-Blind Period [ Time Frame: 28 days ] [ Designated as safety issue: No ]
The time to pain worsening by 30% compared to the value at baseline and a pain score of at least 4 on the 0-10 numerical rating scale on weekly pain assessment. Subjects who drop out due to "lack of efficacy" will be counted as efficacy failures regardless of their pain scores.

Secondary Outcome Measures:

Mean change in pain intensity [ Time Frame: 28 days ] [ Designated as safety issue: No ]
Mean change in pain intensity on the 0-10 numerical rating scale from baseline in the Double-Blind Period.
Mean change in Western Ontario and McMaster Osteoarthritis Index (WOMAC) scores [ Time Frame: 28 days ] [ Designated as safety issue: No ]
Mean change in Western Ontario and McMaster Osteoarthritis Index (WOMAC) scores from Baseline in the Open-Label Period and Double-Blind Period.
The efficacy of milnacipran vs. placebo by time to dropout for all causes [ Time Frame: 70 days ] [ Designated as safety issue: No ]
The efficacy of milnacipran in the Open-Label Period [ Time Frame: 28 days ] [ Designated as safety issue: No ]
The efficacy of milnacipran in the Open-Label Period defined by the change in pain intensity from Baseline to the end of the period and responder proportion.
The difference between milnacipran and placebo in responder proportion in the Double-Blind Period [ Time Frame: 28 days ] [ Designated as safety issue: No ]
The predictive value of "OA sensory sub-type" for predicting the response to milnacipran vs. placebo [ Time Frame: 70 days ] [ Designated as safety issue: No ]
Safety and tolerability by monitoring adverse events [ Time Frame: 70 days ] [ Designated as safety issue: Yes ]


Estimated Enrollment:	50
Study Start Date:	July 2011
Estimated Study Completion Date:	September 2012
Estimated Primary Completion Date:	February 2012 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Milnacipran If subjects meet the criteria to enter the Double-Blind Period, they will be randomized at a 1:1 ratio to take either milnacipran or placebo for 4 weeks. The milnacipran arm will take milnacipran at 200mg/day (100mg twice daily).	Drug: Milnacipran 1 tablet (100mg) by mouth twice daily for 28 days
Placebo Comparator: Placebo If subjects meet the criteria to enter the Double-Blind Period, they will be randomized at a 1:1 ratio to take either milnacipran or placebo for 4 weeks. The placebo group will take 1 tablet twice daily.	Drug: Placebo 1 tablet by mouth twice daily for 28 days

Detailed Description:

The study design is a Double-Blind, Placebo-Controlled, Enriched Enrollment Randomized Withdrawal Study. This means that, upon entry into the study, all subjects will enter an open-label period during which they will take milnacipran for 4 weeks. Subjects will taper their dose up to one 100mg tablet twice daily for a total of 200mg per day. After 4 weeks, the subject will return to the clinic and be re-evaluated.

Only subjects who meet certain criteria are then randomized to continue in the double-blind period of the study. Once a subject is randomized, he or she will take either milnacipran or placebo for another 4 weeks. Following the double-blind period, subjects will be tapered off the study medication and will receive a phone call once each week for 2 weeks for follow-up assessments.

Throughout the study, subjects will complete various questionnaires and other test procedures aimed at sub-typing subjects based on pain mechanisms.

Eligibility


Ages Eligible for Study:	21 Years to 75 Years (Adult, Senior)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Be 21-75 years of age and in good general medical and psychological health
Be able to speak, read, write, and understand English, understand the consent form, complete study related procedures, and communicate with the study staff
Have a negative urine pregnancy test at screening, and use appropriate birth control
Have documented painful Osteoarthritis (OA) of at least one knee for at least 6 months; OA should be of Class I-III and meet the American College of Rheumatology (ACR) clinical classification criteria, defined as:
1. Knee pain and at least 3 of the following 6:
  - Age > 50
  - Morning stiffness < 30 minutes
  - Crepitus on active motion
  - Bony tenderness
  - Bony enlargement
  - No palpable warmth of synovium
2. The target joint must not contain any type of orthopedic and/or prosthetic device
Have a target joint pain average of 5 days per week and have an average pain intensity of at least 4/10 on the 0-10 NRS over the last 24 hours prior to screening
Have stable treatment modalities, e.g. acupuncture, physical therapy
Be willing to stop taking Non-steroidal Anti-inflammatory drugs (NSAIDs) and opioids for the duration of the study

Exclusion Criteria:

Are allergic or intolerant to SNRI; have a previous poor response to a SNRI for OA pain; are currently taking an SNRI or tricyclic antidepressant
Have a body mass index (BMI) >40 kg/m2
Have an Hospital Anxiety and Depression Scale (HADS) score >12 on either subscale or has an established history of major depressive disorder not controlled with medication
Have significant pain outside the target knee, including significant hip or back pain. (Bilateral knee OA allowed.)
Have pain affecting the target knee that is due to any other etiology than OA
Have documented history of inflammatory arthritis including rheumatoid arthritis
Have had local injections in target joint within the past 3 months prior to screening
Have had oral or intramuscular corticosteroids within the past 30 days
Have had worker's compensation claim, disability, or litigation
Have a known history of uncontrolled narrow-angle glaucoma
Have a known history of suicidal ideation
Use monoamine oxidase inhibitors (MAOI) concomitantly
Are allergic or intolerant to acetaminophen
Using opioids 4 or more days per week during the month preceding the screening visit
Have significant history or renal impairment/failure.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01329406

Locations


United States, Massachusetts
Analgesic Solutions	Recruiting
Natick, Massachusetts, United States, 01760
Contact: Karen Cowles, RN, MPH 781-444-9605 ext 121 kcowles@analgesicsolutions.com
Contact: Courtney Lincoln 781-444-9605 ext 119 clincoln@analgesicsolutions.com
Principal Investigator: Stephen L. Wright, M.D.
Sub-Investigator: Nathaniel P. Katz, M.D., M.S.
Sub-Investigator: Eric Osgood, M.D.

Sponsors and Collaborators

Analgesic Solutions

Forest Laboratories

Investigators


Principal Investigator:	Stephen L. Wright, M.D.	Analgesic Solutions

More Information


Responsible Party:	Stephen Wright, M.D., Principal Investigator, Analgesic Solutions
ClinicalTrials.gov Identifier:	NCT01329406 History of Changes
Other Study ID Numbers:	FRX001-2010
Study First Received:	April 4, 2011
Last Updated:	August 16, 2011
Health Authority:	United States: Institutional Review Board

Keywords provided by Analgesic Solutions:


Osteoarthritis (OA) Milnacipran Serotonin-norepinephrine reuptake inhibitor (SNRI) Knee pain

Additional relevant MeSH terms:


Osteoarthritis Arthritis Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Milnacipran Antidepressive Agents Psychotropic Drugs Serotonin Uptake Inhibitors	Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents Serotonin Agents Physiological Effects of Drugs Adrenergic Uptake Inhibitors Adrenergic Agents

ClinicalTrials.gov processed this record on September 23, 2016